TFS Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

TFS Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-13,792	Closed	-$16K	–	996
2016 Q1	$16K	Buy	13,792 +1,130	+9%	+$1.75K	﹤0.01%	977
2015 Q4	$31K	Buy	+12,662	New	+$36.3K	﹤0.01%	723
2015 Q3	–	Sell	-19,818	Closed	-$82K	–	914
2015 Q2	$82K	Sell	19,818 -137,377	-87%	-$548K	0.01%	826
2015 Q1	$681K	Sell	157,195 -165,467	-51%	-$596K	0.07%	447
2014 Q4	$958K	Buy	322,662 +93,622	+41%	+$257K	0.09%	361
2014 Q3	$760K	Buy	+229,040	New	+$599K	0.07%	459

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

Tanaka Capital Management New York $59.9M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TFS Capital's CPRX Position: Q2 2016 in Review

TFS Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2016, closing a stake of 13,792 shares — an estimated $16K sold.

TFS Capital first reported a position in CPRX in Q3 2014 and held it in 6 quarters. The position peaked at $958K in Q4 2014. 62 funds tracked by Wall St. Rank hold CPRX as of Q2 2016.

TFS Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2016 after selling out during the quarter.
TFS Capital sold 13,792 Catalyst Pharmaceutical shares in Q2 2016, an estimated $16K.
TFS Capital first reported a position in Catalyst Pharmaceutical in Q3 2014 and held it in 6 quarters.
TFS Capital's Catalyst Pharmaceutical position peaked at $958K in Q4 2014.
62 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.